Comparison of the efficacy based on clinicopathological characteristics and the safety of first-line treatments for patients with advanced ALK rearrangement non-small cell lung cancer: a network meta-analysis.

Additionally, envonalkib and iruplinalkib were each associated with HRs < 1 across all comparisons for any-grade and grade 3–4 appetite decrease, respectively ( Figure 4e ); however, these latter comparisons did not reach statistical significance.

also in 111,027 other papers